Press Release

NEW YORK, April 4, 2016 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that it will present three abstracts at the EASL 2016 annual meeting to be held April 13-26, 2017 in Barcelona, Spain.

These presentations will disclose updated clinical, pre-clinical and mechanistic data on the activity of NAPs against chronic hepatitis B and hepatitis D infection:

• Updated clinical data from the ongoing REP 301 study assessing the safety and efficacy of REP 2139-Ca combined with pegylated interferon in patients with hepatitis B / hepatitis D co-infection (poster FRI-105).
• In vivo antiviral activity of REP 2139-Ca combined with tenofovir disoproxil fumarate and entecavir (poster THU-177).
• Immunostimulatory properties of REP 2139 and other NAP compounds (poster THU-204).

Replicor’s presentations will be available on the company’s website at the end of the conference at www.replicor.com/science/conference-presentations. For the 2016 EASL Meeting: http://ilc-congress.eu/.

About Replicor
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com.

Media Contact:
Alexandra Peterson
apeterson@makovsky.com
(212) 508-9709